Take a look at our previous reports:

Our JAK1/TYK2 program with GLPG3121

We discovered GLPG3121 as a selective JAK1/TYK2 inhibitor with potential in inflammatory diseases. GLPG3121 is currently being evaluated in a randomized, double-blind, placebo-controlled Phase 1 study to assess the safety, tolerability, and pharmacokinetics in healthy volunteers with a decision to continue further development of the compound expected in 2022.

A compound in Phase 1 targeting JAK1/TYK2 directed toward inflammation (IBD). Development was stopped in July 2022